Codexis (CDXS) Appoints Raymond De Vre to its Board

Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Raymond De Vré, PhD, to the Company’s Board of Directors.

“We are thrilled to have Raymond join the Codexis Board of Directors. He will be an invaluable resource to Codexis,” said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. “Raymond brings a deep understanding of the commercial and regulatory landscape as well as direct experience in oligonucleotide manufacturing.”

“Codexis and its ECO Synthesis platform represent the next generation of innovation for oligonucleotide development and manufacturing. I’m excited to partner with the rest of the Board and the executive team as we build a strong and sustainable business on the foundation of this unique technology platform,” said Dr. De Vré.

Dr. De Vré brings over 20 years of executive-level experience to Codexis. He currently serves as Managing Director at RADV Advisory, an independent strategic and operational advisory company focused on investments in the global healthcare and contract development and manufacturing organization (CDMO) space. Prior to founding RADV Advisory, he was the Chief Executive Officer of PolyPeptide Group, a CDMO focused on peptide- and oligonucleotide-based therapies for pharmaceutical and biotech companies globally. Prior to PolyPeptide, Dr. De Vré held multiple senior leadership roles at Dr. Reddy’s Laboratories, including Senior Vice President, Head of Biologics, and served as a member of the Management Council. Earlier in his career, he was a Partner at McKinsey & Company, working mostly in the pharmaceutical and biotech practice. Dr. De Vré holds a PhD in Applied Physics from Stanford University and a master’s degree in engineering from Université Libre de Bruxelles.

You May Also Be Interested In